Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05409989
Other study ID # CL11023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 20, 2022
Est. completion date November 2029

Study information

Verified date April 2024
Source Microvention-Terumo, Inc.
Contact Amy Bowles
Phone 678-858-0992
Email Amy.bowles@microvention.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.


Recruitment information / eligibility

Status Recruiting
Enrollment 154
Est. completion date November 2029
Est. primary completion date September 2029
Accepts healthy volunteers No
Gender All
Age group 22 Years to 75 Years
Eligibility Inclusion Criteria: Subjects for this study must meet ALL the following criteria: 1. Subject has single target aneurysm in the internal carotid artery from petrous segment to the terminus of the internal carotid artery. 2. The parent artery diameter must be 2.0 - 5.0 mm distal and/or proximal to the target intracranial aneurysm. 3. Negative pregnancy test (serum or urine) in a female subject who has had menses in the last 18 months. 4. Subject commits to return to the investigational site for the 30- day, 6-month, 12-month, 2-year, 3-year, and 5-year follow-up evaluations. 5. The subject or his/her authorized representative must sign the IRB-approved written informed consent form prior to the start of any study procedures. 6. The subject has a modified Rankin Scale (mRS) = 2. 7. The subject has a wide-necked ( =4mm or dome-to-neck ratio <2) saccular or fusiform aneurysm. Exclusion Criteria: Subjects shall be excluded from the study if ANY of the following conditions exist: 1. Subject who suffers from a subarachnoid hemorrhage in the last 60 days. 2. Subject who suffers from intracranial hemorrhage in the last 30 days. 3. Subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region. 4. Subject with symptomatic extracranial or intracranial stenosis of the parent artery (>50%) proximal to the target aneurysm. 5. Subject with an irreversible bleeding disorder, a platelet count < 100 x 103 cells/mm3 or known platelet dysfunction or a contraindication to or inability to tolerate anticoagulants/antiplatelet agents or thrombolytic drugs. 6. Subject with history of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding. 7. Subject with known hypersensitivity to any component of the treatment device that cannot be medically controlled. 8. Subject with documented contrast allergy, or other condition that prohibits imaging. 9. Evidence of active bacterial infection at the time of treatment. 10. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%. 11. Subject with a pre-existing stent in place at the target aneurysm. 12. Subject who is unable to complete the required follow-ups. 13. Subject who is pregnant, breastfeeding, or of childbearing potential and unwilling to prevent pregnancy during their participation in the study. 14. Subject has a serious or life-threatening comorbidity that could confound study results and/or prevent completion of 5-year followup. 15. Subject is enrolled in another device or drug study in which participation could confound study results. 16. Subject has absent femoral pulses or other condition preventing femoral access, or is planned to be treated using a radial access approach.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FRED™ X™
The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

Locations

Country Name City State
United States Albany Medical Center Albany New York
United States University of Maryland Baltimore Maryland
United States Massachusetts General Brigham Incorporated Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States University at Buffalo Buffalo New York
United States Ohio Health Riverside Research Institute Columbus Ohio
United States Ohio State University Columbus Ohio
United States Memorial Healthcare Systems Hollywood Florida
United States University of Iowa Iowa City Iowa
United States University of Kansas Kansas City Kansas
United States Baptist Healthcare System Louisville Kentucky
United States Norton Healthcare Louisville Kentucky
United States Northwell Health Manhasset New York
United States Ochsner Health New Orleans Louisiana
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Orlando Health Orlando Florida
United States Thomas Jefferson University Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States Stony Brook University Stony Brook New York
United States ProMedica Toledo Hospital Toledo Ohio
United States UMass Memorial Health Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Microvention-Terumo, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Safety Endpoint Part 1: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure. Major stroke is defined as a new neurological event that persists for >24 hours and results in a =4-point increase in the NIHSS score compared to baseline or compared to any subsequent lower score. 30-days
Primary Primary Safety Endpoint Part 2: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurological death is defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a neurologic cause. 12 months
Primary Primary Effectiveness Endpoint: The percent of subjects with (1) complete (100%) occlusion of the target aneurysm and =50% stenosis of the parent artery at the target IA, and (2) in whom an alternative treatment of the target IA had not been performed. (1) Complete (100%) occlusion of the target aneurysm is assessed utilizing the Raymond-Roy Scale (Raymond Roy Class 1) and =50% stenosis of the parent artery at the target IA), and in whom an alternative treatment of the target IA had not been performed. The study will utilize independent Core Laboratory to adjudicate all angiographic outcomes, including aneurysm occlusion status and parent artery stenosis. (2) Alternative treatment is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of in-stent stenosis. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04870047 - Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation N/A
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT05665309 - Interest of Pre-operative Use of 3D Printing for Endovascular Treatment of Unruptured Intracranial Aneurysms With Intrasaccular Flow Disruptor N/A
Completed NCT02783339 - Neuroform Atlas Stent for Intracranial Aneurysm Treatment
Withdrawn NCT01194388 - Axium Coil in Completing Endovascular Aneurysm Surgery Study
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Completed NCT03680742 - Contour Neurovascular System - European Pre-Market Unruptured Aneurysm N/A
Completed NCT04872842 - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on 100 Regional Medical Centers in China and Population Follow-up Study
Terminated NCT02532517 - Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device N/A
Completed NCT03663257 - Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
Recruiting NCT06189950 - Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE N/A
Recruiting NCT05608122 - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on Regional Medical Centers in China and Population Follow-up Study (Phase Ⅱ)
Recruiting NCT03661463 - Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT). Phase 2
Completed NCT02609867 - A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise) N/A
Active, not recruiting NCT02292017 - Prospective Packing Density With Target Coils I N/A
Active, not recruiting NCT01872741 - Minipterional Versus Pterional Craniotomy N/A
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Completed NCT00777907 - Complete Occlusion of Coilable Aneurysms Phase 3
Completed NCT00777088 - Pipeline for Uncoilable or Failed Aneurysms N/A
Not yet recruiting NCT05060185 - The Flow Diverter for Treating Patients With Intracranial Aneurysms N/A